| Reconciliation Of Operating Profit Loss From Segments To Consolidated |
For additional information on the year over year change of segment expenses refer to Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
|
Nine Months Ended
September 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
|
|
(in thousands) |
|
|
(in thousands) |
|
Research and development expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Manufacturing of preclinical and clinical supplies |
|
$ |
17,521 |
|
|
$ |
12,997 |
|
|
$ |
42,169 |
|
|
$ |
29,639 |
|
Personnel |
|
|
13,125 |
|
|
|
11,700 |
|
|
|
38,323 |
|
|
|
35,066 |
|
Clinical trials |
|
|
13,362 |
|
|
|
10,872 |
|
|
|
35,795 |
|
|
|
28,453 |
|
License of intellectual property |
|
|
— |
|
|
|
— |
|
|
|
3,000 |
|
|
|
— |
|
Development services |
|
|
2,379 |
|
|
|
3,677 |
|
|
|
6,913 |
|
|
|
11,442 |
|
Other research and development costs (1) |
|
|
757 |
|
|
|
578 |
|
|
|
2,727 |
|
|
|
1,880 |
|
General and administration expenses |
|
|
7,563 |
|
|
|
6,764 |
|
|
|
22,097 |
|
|
|
23,150 |
|
Interest income |
|
|
(2,144 |
) |
|
|
(1,808 |
) |
|
|
(4,824 |
) |
|
|
(4,705 |
) |
Interest expense |
|
|
511 |
|
|
|
584 |
|
|
|
1,664 |
|
|
|
1,449 |
|
Other income, net |
|
|
(21 |
) |
|
|
(498 |
) |
|
|
(278 |
) |
|
|
(437 |
) |
Net loss |
|
$ |
53,053 |
|
|
$ |
44,866 |
|
|
$ |
147,586 |
|
|
$ |
125,937 |
|
(1) Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.
|